Micafungin Teva (Micafungin Sodium)

Micafungin inhibits the fungal enzyme β‑(1,3)‑D‑glucan synthase, which is essential for building β‑(1,3)‑D‑glucan, a key structural component of the fungal cell wall. Disruption of cell‑wall synthesis leads to osmotic instability and cell death, while human cells are largely unaffected because they lack this pathway.

The specific dose of Micafungin Teva is determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and the indication being treated. Healthcare professionals follow established guidelines and adjust the regimen as needed for safety and efficacy.

The safety of Micafungin Teva in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician after a careful risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, whereas azoles inhibit ergosterol synthesis and polyenes bind directly to membrane sterols. Echinocandins like micafungin generally have a favorable safety profile and are effective against many Candida species, including those resistant to azoles.

Micafungin Teva should be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside this range.

Micafungin Teva is administered intravenously. The infusion is given over a period of usually 60 minutes, using a sterile diluent as recommended by the manufacturer. Administration should be performed by qualified healthcare personnel in a clinical setting.

Serious risks include severe hepatic dysfunction, anaphylactic reactions, and rare skin disorders such as Stevens‑Johnson syndrome. Patients should be monitored for signs of liver injury, hypersensitivity, and any unusual skin changes, and the drug should be discontinued promptly if these events occur.

Micafungin Teva is contraindicated in patients with a known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, as well as those receiving interacting medications that could increase toxicity.